Loading
Harvard Bioscience Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Frost Mark T, was filed 01 Apr 2026.
Harvard Bioscience Inc: what insiders have been doing
Headquartered in Holliston, United States, Harvard Bioscience Inc belongs to the Healthcare & Pharma sector and traces its origins to 1901. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 10 filings came from 6 insiders.
Only purchases show up on the open market, 4 purchases in all worth €141k, filed by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Snider William filed the largest purchase, €55k, on 18 March 2026. The buyers include 2 senior executives, 1 finance chief and 1 chief executive.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The latest purchase dates back some time: it was published 200 days ago, on 1 April 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.
With 10 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 18 purchases and 1 sale. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 86.5 m USD and net income at -56.7 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
104
Thresholds
n/a
Buy Volume
€890,553
18 ops. · all time
Sell Volume
€328,973
1 ops. · all time
Who traded when
BuySaleJohn D. Duke1 buy
Mark T. Frost1 buy
Stephen J. Denelsky1 buy
William Snider1 buy
Since the insiders bought
- +16.3%Entry US$5.20 · Close at T+90 US$6.05
- +7.1%Entry US$5.60 · Close at T+90 US$6.00
- +7.1%Entry US$5.60 · Close at T+90 US$6.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,248 of 23,476 companies
35.8
score / 100
Value44
Quality28
FCF yld13%
Earn yld-156%
EV/EBITDA·
ROE-90%
Gross mgn58%
Net mgn-66%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.98
Analyst consensus
1 analysts2.50/5
US$7.50Target US$7.50(-6%)US$7.50
Income statement
RevenueUS$86.6M
Gross profitUS$49.9M58% margin
EBITDA-US$46.5M-54% margin
Net income-US$56.7M-11.9% margin
Valuation
PER (forward)12.4x
P/Book4.9x
Beta1.53
Balance sheet & cash
Market capUS$36.3M
Total debtUS$44.3M
Free Cash FlowUS$4.9M
Debt / Equity596%
Profitability & ownership
ROE-89.9%
ROA1.6%
% insiders9.4%
% institutions42.1%
Last declaration on 11 June 2026
Declarations104 total
16,556 sharesCommon StockSEC:0001171843-26-004058:0
16,556 sharesCommon StockSEC:0001171843-26-004057:0
16,556 sharesCommon StockSEC:0001171843-26-004056:0
30,000 shares0Common StockSEC:0001171843-26-002156:0
5,000 shares@ US$5.00100.0% of flowCommon StockSEC:0001171843-26-002155:0
Canonical exit: 14 Jun 2026 (T+90)
75,000 shares0Common StockSEC:0001171843-26-001843:0
12,525 shares@ US$4.99100.0% of flowCommon StockSEC:0001171843-26-001689:0
Canonical exit: 14 Jun 2026 (T+90)
10,000 shares@ US$4.87100.0% of flowCommon StockSEC:0001171843-26-001732:0
Canonical exit: 15 Jun 2026 (T+90)
5,000 shares@ US$5.01100.0% of flowCommon StockSEC:0001171843-26-001645:0
Canonical exit: 14 Jun 2026 (T+90)
110,000 shares0Common StockSEC:0001171843-25-008127:0
110,000 shares0Common StockSEC:0001171843-25-006325:0
49,048 shares0Common StockSEC:0001104659-25-080209:0
500,000 shares0Common StockSEC:0001104659-25-076302:0
110,000 shares0Common StockSEC:0001104659-25-070938:0
110,000 shares0Common StockSEC:0001104659-25-069051:0
110,000 shares0Common StockSEC:0001104659-25-069048:0
100,000 shares0Common StockSEC:0001104659-25-048461:0
38,413 shares@ US$0.68861.9% of flowCommon StockSEC:0001104659-25-026702:0
5,687 shares@ US$0.688610.0% of flowCommon StockSEC:0001104659-25-026705:0
145,365 shares0Common StockSEC:0000921895-25-000025:0
4,731 shares@ US$1.9825.2% of flowCommon StockSEC:0000921895-24-003051:0
56,915 shares@ US$1.988.3% of flowCommon StockSEC:0000921895-24-003052:0
3,797 shares@ US$1.9820.2% of flowCommon StockSEC:0000921895-24-003051:1
10,000 shares@ US$2.912.1% of flowCommon StockSEC:0000921895-24-001418:0
Canonical exit: 11 Sept 2024 (T+90)
20,000 shares@ US$3.074.3% of flowCommon StockSEC:0000921895-24-001362:0
Canonical exit: 4 Sept 2024 (T+90)
25 of 104 declarations
About Harvard Bioscience Inc
Harvard Bioscience Inc. is a U.S.-based life-sciences instrumentation company listed on the Nasdaq under the ticker HBIO, in the United States. Headquartered in Holliston, Massachusetts, the company traces its roots back to 1901, when it began as Harvard Apparatus. That long operating history gives it a distinctive position in scientific tools, with a brand legacy that spans more than a century in laboratory research and biomedical instrumentation.
Today, Harvard Bioscience develops, manufactures, and sells technologies, products, and services that support fundamental advances in life-science applications. Its customer base includes academic research institutions, pharmaceutical and biotechnology companies, and contract research organizations. The company’s solutions are used across drug and therapy discovery, bioproduction, preclinical testing, and safety pharmacology. In practical terms, HBIO operates as a specialist supplier to the research infrastructure that underpins early-stage discovery and translational science.
Read moreShow less
Its commercial footprint is built around a portfolio of brands with strong technical recognition, including Harvard Apparatus, Data Sciences International (DSI), Biochrom, BTX, Multi Channel Systems (MCS), HEKA, Panlab, Warner Instruments, and others. This brand structure allows the company to address multiple adjacent niches such as physiology, electrophysiology, cell and molecular instrumentation, telemetry, organoid research systems, and other specialized laboratory applications. Rather than competing as a broad commoditized supplier, Harvard Bioscience positions itself as a focused developer of niche tools and integrated workflows for demanding scientific users.
From a competitive standpoint, the company operates in a fragmented but specialized market where technical differentiation, application expertise, and installed-brand reputation matter. Its competitive edge is tied to the breadth of its product set, the legacy of its brands, and its ability to serve researchers who need purpose-built instrumentation rather than off-the-shelf generic lab equipment. The business is international in scope, with sales across North America, Europe, Asia, and other global markets.
Recent developments have been notable. In 2025, the company reported improving gross margin trends and positive cash flow from operations in several quarters, while continuing to focus on cost discipline and balance-sheet repair. Management also highlighted new product adoption, including MeshMEA organoid systems and SoHo telemetry systems, and announced an expanded distribution agreement with Fisher Scientific in the United States. These updates suggest an operating model still in transition: the company is working to grow its core franchises while strengthening financial flexibility. For investors, Harvard Bioscience is best viewed as a small-cap U.S. healthcare-tools name on the Nasdaq with meaningful niche exposure, a long operating heritage, and ongoing execution risk around growth, leverage, and restructuring.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
